These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33515688)

  • 1. Comparison of two empirical prolonged infusion dosing regimens for meropenem in patients with septic shock: A two-center pilot study.
    Eisert A; Lanckohr C; Frey J; Frey O; Wicha SG; Horn D; Ellger B; Schuerholz T; Marx G; Simon TP
    Int J Antimicrob Agents; 2021 Mar; 57(3):106289. PubMed ID: 33515688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units.
    Jaruratanasirikul S; Thengyai S; Wongpoowarak W; Wattanavijitkul T; Tangkitwanitjaroen K; Sukarnjanaset W; Jullangkoon M; Samaeng M
    Antimicrob Agents Chemother; 2015; 59(6):2995-3001. PubMed ID: 25753628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes of PK/PD of Meropenem in patients with abdominal septic shock and exploration of clinical rational administration plan: a prospective exploratory study.
    Wang Y; Li H; Wang D; Li Y; Shen Y; Fu Y; Li Y; Gao M; Zhang D
    Sci Rep; 2024 May; 14(1):10173. PubMed ID: 38702351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
    O'Jeanson A; Larcher R; Le Souder C; Djebli N; Khier S
    Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):695-705. PubMed ID: 34403127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximally effective dosing regimens of meropenem in patients with septic shock.
    Sjövall F; Alobaid AS; Wallis SC; Perner A; Lipman J; Roberts JA
    J Antimicrob Chemother; 2018 Jan; 73(1):191-198. PubMed ID: 28961812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the optimal loading dose of broad-spectrum β-lactam antibiotics in septic patients? Results from pharmacokinetic simulation modelling.
    Delattre IK; Hites M; Laterre PF; Dugernier T; Spapen H; Wallemacq PE; Jacobs F; Taccone FS
    Int J Antimicrob Agents; 2020 Oct; 56(4):106113. PubMed ID: 32721604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining optimal dosing of ciprofloxacin in patients with septic shock.
    Roberts JA; Alobaid AS; Wallis SC; Perner A; Lipman J; Sjövall F
    J Antimicrob Chemother; 2019 Jun; 74(6):1662-1669. PubMed ID: 30809648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.
    Ulldemolins M; Soy D; Llaurado-Serra M; Vaquer S; Castro P; Rodríguez AH; Pontes C; Calvo G; Torres A; Martín-Loeches I
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5520-8. PubMed ID: 26124172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?
    Öbrink-Hansen K; Juul RV; Storgaard M; Thomsen MK; Hardlei TF; Brock B; Kreilgaard M; Gjedsted J
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7018-26. PubMed ID: 26349823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
    Burger R; Guidi M; Calpini V; Lamoth F; Decosterd L; Robatel C; Buclin T; Csajka C; Marchetti O
    J Antimicrob Chemother; 2018 Dec; 73(12):3413-3422. PubMed ID: 30304491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.
    Busse D; Simon P; Schmitt L; Petroff D; Dorn C; Dietrich A; Zeitlinger M; Huisinga W; Michelet R; Wrigge H; Kloft C
    Clin Pharmacokinet; 2022 May; 61(5):655-672. PubMed ID: 34894344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic Analysis of Meropenem After Intravenous Infusion in Korean Patients With Acute Infections.
    Kim YK; Lee DH; Jeon J; Jang HJ; Kim HK; Jin K; Lim SN; Lee SS; Park BS; Kim YW; Shin JG; Kiem S
    Clin Ther; 2018 Aug; 40(8):1384-1395. PubMed ID: 30093133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation.
    Kong L; Tang Y; Zhang X; Lu G; Yu M; Shi Q; Wu X
    Ann Pharmacother; 2017 Nov; 51(11):970-975. PubMed ID: 28677407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: implications for empirical therapy against Gram-negative bacteria.
    Kothekar AT; Divatia JV; Myatra SN; Patil A; Nookala Krishnamurthy M; Maheshwarappa HM; Siddiqui SS; Gurjar M; Biswas S; Gota V
    Ann Intensive Care; 2020 Jan; 10(1):4. PubMed ID: 31925610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study.
    Zhao HY; Gu J; Lyu J; Liu D; Wang YT; Liu F; Zhu FX; An YZ
    Chin Med J (Engl); 2017 May; 130(10):1139-1145. PubMed ID: 28485312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Huisinga W; Zander J; Kloft C
    Int J Antimicrob Agents; 2019 Sep; 54(3):309-317. PubMed ID: 31229669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients.
    Mathew SK; Mathew BS; Neely MN; Naik GS; Prabha R; Jacob GG; K S; Fleming DH
    Ther Drug Monit; 2016 Oct; 38(5):593-9. PubMed ID: 27454665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal Dosing of Meropenem in a Small Cohort of Critically Ill Children Receiving Continuous Renal Replacement Therapy.
    Tan WW; Watt KM; Boakye-Agyeman F; Cohen-Wolkowiez M; Mok YH; Yung CF; Chan YH
    J Clin Pharmacol; 2021 Jun; 61(6):744-754. PubMed ID: 33314163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying optimal dosing strategies for meropenem in the paediatric intensive care unit through modelling and simulation.
    Morales Junior R; Mizuno T; Paice KM; Pavia KE; Hambrick HR; Tang P; Jones R; Gibson A; Stoneman E; Curry C; Kaplan J; Tang Girdwood S
    J Antimicrob Chemother; 2024 Oct; 79(10):2668-2677. PubMed ID: 39092928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.